Phibro Animal Health beat earnings estimates in all 4 of the last 4 quarters with average surprise of 16.7% and a return on equity of 30%, but carries negative free cash flow at 19% of net income and a debt-to-equity ratio of 2.2 that raises value-trap warning flags alongside the attractive forward price-to-earnings of 9.7x.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Strong Return On Equity→Stable
- Negative Free Cash Flow Red Flag→Stable
- +1 more pillar — see the Why tab for full reasoning
Phibro Animal Health Corporatio (PAHC) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $34.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: livestock sector; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4).
Phibro Animal Health is a global animal health and mineral nutrition company selling roughly 800 product lines in about 90 countries to approximately 4,500 customers, across three segments: Animal Health (antibacterials, anticoccidials, vaccines), Mineral Nutrition, and... Read more
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $34.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: livestock sector; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4). Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Score 5.8/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Phibro Animal Health Corporatio
About Phibro Animal Health Corporatio
Phibro Animal Health generated $1,296 million in net sales for the year ended June 30, 2025, with its Animal Health segment (antibacterials, anticoccidials, nutritional specialties and vaccines) contributing 74% of the total, Mineral Nutrition 20%, and Performance Products 6%. The United States accounted for 57% of net sales, followed by Latin America and Canada at 23%, and the company markets roughly 800 product lines to approximately 4,500 customers across some 90 countries.
Phibro's Animal Health segment earns revenue from antibacterials and anticoccidials sold as medicated feed additives (MFAs) — led by Stafac, Terramycin, and Mecadox plus the Zoetis-acquired Aureomycin, BMD, and LincoSpectin lines — alongside nutritional specialty products such as OmniGen and Animate and vaccines including autogenous Tailor-Made and Phi-Shield lines. Approximately 40% of MFA and other product sales in fiscal 2025 went to the poultry industry, with swine, beef, and dairy cattle customers accounting for the rest. Mineral Nutrition sells trace-mineral formulations (zinc, manganese, copper, iron) priced largely off underlying commodity metal costs, concentrated in North America, while Performance Products sells specialty ingredients to the personal care, industrial chemical, and chemical catalyst industries, predominantly in the United States. The October 2024 acquisition of Zoetis's medicated feed additive portfolio — more than 37 product lines across roughly 80 countries and six manufacturing sites — contributed $208.2 million to net sales in the year ended June 30, 2025.
Show full overview
Phibro discloses that its business is currently concentrated in the livestock sector and that a material portion of its sales and gross profits are generated by antibacterials and other related products, a combination that ties results closely to how regulators treat that drug class. The 10-K specifically flags the potential FDA withdrawal of approval of Mecadox (carbadox), a swine antibacterial, alongside broader restrictions on antibacterial use in food-producing animals tied to FDA Guidance 273 and similar initiatives globally — regulatory actions that would remove or narrow specific revenue lines rather than merely raise compliance costs.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Phibro Animal Health Corporatio's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-25Recent Developments — Phibro Animal Health Corporatio
Latest news
- NEWS Phibro Animal Health Corp (PAHC) Shares Fall 3.3% -- GF Value Sa - GuruFocus — GuruFocus negative
- NEWS (PAHC) Phibro Animal Health Expects Fiscal 2027 Revenue Range $1.55B - $1.60B, vs. FactSet Est of $1.55B - marketscreene — marketscreener.com neutral
- NEWS Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - StockStory — StockStory positive
- NEWS Phibro Animal Health (PAHC) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - FinancialContent — FinancialContent positive
Generated 2026-09-26T04:01:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductlivestock sector10-K Item 1: 'Our business is currently concentrated in the livestock sector.'
- MEDIUMCustomerpoultry industry (MFAs and other)40%10-K Item 1: 'Approximately 40% of our MFAs and other sales in fiscal year 2025 were to the poultry industry, with sales to swine, beef and dairy cattle and other customers accounting for the remainder.'
- MEDIUMProductantibacterials and other related products10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'
- MEDIUMGeographicIsraeli and Brazilian operations10-K Item 1A: 'our dependence on our Israeli and Brazilian operations'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02LOWDirector Joyce J. Lee informed the company she intends to resign effective April 15, 2026. No disagreement with the Company on any operational, policy, or practice matter cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $34.63 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: livestock sector; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4). Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Prior stop was $32.23. Score 5.8/10, moderate confidence.
Take-profit target: $38.28 (+10.6% upside). Prior stop was $32.23. Stop-loss: $32.23.
Concentration risk — Product: livestock sector; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4); Leverage penalty (D/E 2.1): -1.5.
Phibro Animal Health Corporatio trades at a P/E of 14.0 (forward 8.8). TrendMatrix value score: 8.4/10. Verdict: Sell.
10 analysts cover PAHC with a consensus score of 2.5/5. Average price target: $44.
What does Phibro Animal Health Corporatio do?Phibro Animal Health is a global animal health and mineral nutrition company selling roughly 800 product lines in about...
Phibro Animal Health is a global animal health and mineral nutrition company selling roughly 800 product lines in about 90 countries to approximately 4,500 customers, across three segments: Animal Health (antibacterials, anticoccidials, vaccines), Mineral Nutrition, and Performance Products. Animal Health generated 74% of fiscal 2025 net sales of $1,296 million, boosted by its October 2024 acquisition of Zoetis's medicated feed additive portfolio for about $297.5 million.